Introduction:
Reovirus type 3 Dearing (reovirus; REOLYSIN ® ; Oncolytics Biotech Inc) is a wild-type member of the Reoviridae family and is nonpathogenic in humans. Infections are usually asymptomatic, however, reovirus infection of cancer cells results in specific cytolysis.Activated signalling pathways downstream of KRAS or EGFR suppress the activity of double stranded RNA activated protein kinase (PKR), which normally inactivates viral replication (1, 2) . Therefore reovirus is being tested as an anti cancer therapy targeted at KRAS mutant tumors.
Systemic administration of reovirus has been tested in human subjects in two phase I monotherapy trials. The first trial used a single infusion of 1x10 8 to 3x10 10 tissue culture infective dose (TCID) 50 every 4 weeks and the second trial tested treatment schedule infusing up to 3x10 10 TCID 50 5 consecutive days every 4 weeks (3, 4) .
Neither study observed dose limiting toxicities (DLT). Commonly observed mild toxicities included fever, fatigue and headache. Dose escalation stopped at 3x10 10 TCID 50 as this was considered the manufacturing limit for reovirus. Importantly, both studies showed evidence of viral replication in tumor tissue samples taken after treatment, indicating that systemic treatment with reovirus delivers the virus to the tumor site. The viral shedding after systemic delivery was minimal. The conclusion from these studies is that intravenous single agent reovirus administration is safe.
This trial studies the combination of reovirus with gemcitabine. Exploration of combinations of reovirus with chemotherapy in clinical trials is an important step towards unlocking the full potential of reoviral therapy (5, 6, 7) . The combination of systemic reovirus administration with concomitant chemotherapy, including gemcitabine has shown synergy in various in vivo model systems (8, 7, 6) . Lung and pancreatic cancer are tumor types that harbour common mutations in the KRAS oncogene and should be targeted by reovirus treatment. For both these diseases gemcitabine either as combination or single agent is standard of care treatment. In vivo testing of the combination of reovirus and gemcitabine in mice showed remarkable anti-tumor effects with pathologic complete remissions in 4/5 mice (9) .
These data pose a strong rationale to combine reovirus and gemcitabine.
Research. The combination of reovirus-based oncolytic therapy with chemotherapy is not expected to result in overlapping toxicity based on the known toxicity profiles; however chemotherapy may blunt an immune response to viral antigens and thereby may increase the exposure and toxicity of the virus to normal tissues (5) . Exposure to reovirus results in the induction of neutralizing anti-reovirus antibodies (NARA) and baseline NARA levels can be detected in up to 100% of healthy human adults (5).
The immunological response to reovirus infusion has been documented in Phase I studies and lead to a fast and effective increase in NARA levels (10) . The coadministration of full dose cyclophosphamide with reovirus in mice resulted in marked tumor regression, however it also induced lethal cardiac toxicity (11) . Reoviral replication could be detected in cardiac cells due to complete suppression of the NARA response and led to a massive myocarditis. Lower doses of cyclophosphamide were well tolerated and blunting of the NARA response did lead to better reovirus delivery to the tumor. A number of reports have shown that immunosuppression given concomitantly with reovirus treatment in mice, using low dose cyclophosphamide, cyclosporine or antibodies to CD4/CD8 improves treatment efficacy (8, 12 ). This trial is the first study to report a combination of reovirus with chemotherapy in humans and we included NARA measurements to document any changes that could contribute to toxicity and potential efficacy.
Here we report the results of a Phase I, open-label, dose-escalation study of the combination of reovirus and gemcitabine that aimed to determine the safety and tolerability of systemic reovirus when co-administered with gemcitabine treatment and thus determine the MTD for reovirus in this combination. Secondary endpoints included the characterization of the immune response to reovirus given with gemcitabine; to evaluate the pharmacokinetics of gemcitabine when combined with reovirus; and to describe any anti-tumor activity.
Research. Gemcitabine was reconstituted according to the manufacturer's instructions and was administered as a 30-minute intravenous infusion prior to reovirus administration. Concentrations of gemcitabine were quantified in plasma using an LC-MS/MS method, with a lower limit of quantification of 5 ng/mL according to published methodology and compared to historic data (14, 15, 16 The temporal relation suggests a causal relation between this event and the reovirus/gemcitabine treatment. As 2/2 patients experienced a DLT in the first cohort, the protocol was amended and the dose of reovirus was lowered to 1x10 9 TCID 50 on D1 of each cycle. The subsequent cohorts with reovirus treatment only on D1 did show one more DLT at the dose level of 3x10 10 TCID 50 . This patient had a grade 3 rise in liver enzymes (ALT) which occurred during the first cycle. This patient was rechallenged with gemcitabine alone in the second cycle and did not develop liver enzyme abnormalities in this cycle; therefore this event was deemed related to the combination of reovirus and gemcitabine.
Reovirus (REOLYSIN
Safety:
Treatment related adverse events for reovirus were similar to those observed in the previous two Phase I studies. The treatment related toxicities that occurred in more than 10% of patients are given in As 2/3 DLTs were related to liver enzyme rises and had not been observed in the single agent phase I trials, we analyzed the data on liver enzyme changes more carefully. Of note, both patients with grade 3 liver enzyme elevations had concomitant antipyretic medication of acetaminophen (paracetamol or APAP), which also may have contributed to liver toxicity. We plotted the levels of ALT relative to baseline to determine the changes over time for the first cycle for the different cohorts (Fig. 1A) . Interestingly, a peak in ALT was seen at C1 D15 with a trend towards increased liver enzyme levels at higher doses of reovirus. The same trend was confirmed by plotting the maximal increase during the first cycle of treatment ( Furthermore, pharmacokinetic parameters of gemcitabine (CL and Vss) administered in combination with reovirus were not appreciably different to corresponding parameters derived from previously-conducted studies in patients with cancer using similar dosing regimens.
NARA response and immune monitoring.
Fourteen out of sixteen patients had evaluable samples for NARA determination.
Unfortunately, samples for the first two patients were not available. The results per patient are given in table 3. One of 14 patients reached the peak NARA titer at D15 of cycle 1, 2/14 patients had their final NARA titer measurement at D15 of cycle 1 and 11/14 patients did not reach their peak NARA titer at this point in time. The peak titer of NARA was >1/10.000 in 5/14 patients and did not reach 1/100.000 in any of the patients tested (Fig. 2) . Compared to the results in the monotherapy Phase I trial that reported NARA titers (10), the NARA response is attenuated both in time to induction, as well as peak levels (table 4) .
Response evaluation
Ten patients were evaluable for response as determined by the presence of measurable disease and receiving at least two cycles of treatment. One patient with metastatic nasopharyngeal carcinoma had a partial response according to RECIST after 4 cycles of treatment and one patient with breast cancer had a clinical improvement of symptoms and a minor decrease in tumor size. This patient had failed multiple lines of treatment including radiation, epirubicin, cyclophosphamide, docetaxel, trastuzumab, vinorelbin, and capecitabine. Unfortunately, no material was available to test EGFR and KRAS mutations in the patients that responded.
Furthermore, 6 other patients had SD for 4-8 cycles, for a total disease control rate Discussion:
We present the results of a Phase I trial combining reovirus and gemcitabine. We did not formally determine the MTD of the combination but based on our three patient cohorts we consider 1x10 10 Attenuation of a NARA response may increase exposure of normal tissues to the virus and thus increase toxicity but could also be beneficial for the delivery of virus to the tumor (8, 12, 11) . Our study is the first to suggest that co-administration of gemcitabine potentially results in more pronounced reovirus or gemcitabine induced side effects due to attenuation of the NARA response. We are currently performing a trial to titrate cyclophosphamide doses in combination with systemic reovirus therapy.
This trial has an endpoint based on NARA titers combined with toxicity and will be an important step forward in determining whether chemotherapy induced immune suppression is effective in enhancing the anti-tumor effect of reovirus therapy.
Moreover, the combination of reovirus with gemcitabine could also have a separate effect on cellular immunity which may play a separate role in its anti-cancer activity (21) . Gemcitabine has been reported to affect the balance of the cellular immunity towards a more effective anti-tumor efficacy of the reovirus treatment independent of attenuation of the NARA response (22, 23) .Therefore, immune monitoring measuring both cellular components and NARA levels, should be considered as part of future trials exploring reovirus in combination with chemotherapy.
This trial had a patient with nasopharyngeal cancer that showed an objective response on imaging. This finding is potentially interesting as nasopharyngeal carcinoma is associated with infections with the Epstein Barr Virus (EBV). EBV infection is known to induce the expression of EGFR, a potential explanation for the observed efficacy (24). Overall these data indicate that this combination warrants further exploration. 
